Nothing Special   »   [go: up one dir, main page]

JO3796B1 - ميوثينات إنترلوكين 2 لتمدد الخلايا المنظمة t - Google Patents

ميوثينات إنترلوكين 2 لتمدد الخلايا المنظمة t

Info

Publication number
JO3796B1
JO3796B1 JOP/2014/0119A JOP20140119A JO3796B1 JO 3796 B1 JO3796 B1 JO 3796B1 JO P20140119 A JOP20140119 A JO P20140119A JO 3796 B1 JO3796 B1 JO 3796B1
Authority
JO
Jordan
Prior art keywords
muteins
regulatory cells
interleukin
expansion
molecules
Prior art date
Application number
JOP/2014/0119A
Other languages
English (en)
Inventor
T Pearson Joshua
Li Li
Karow Margaret
A Gavin Marc
Kannan Gunasekaran
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of JO3796B1 publication Critical patent/JO3796B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

يتم في هذا الاختراع إعداد جزيئات ميوتينات IL2. وجزيئات اندماج بين Fc وميوتين IL2 والتي يفضل أن تتمدد وتنشط خلايا T التنظيمية ويمكن أن تنتج بكميات كبيرة. ويتم أيضا في هذا الاختراع إعداد جزيئات IgG1 Fc آدمية مغايرة تفتقد بوظيفة مؤثرة منخفضة جدا وثبات مرتفع على الرغم من افتقاد إضافة الجليكوزيل عند N297. وأيضا يتم في هذا الاختراع إعداد ببتيدات ربط والتي تحتوي على وحدات جليكوزيلات عند التعبير عنها في خلايا الثدييات.
JOP/2014/0119A 2013-03-14 2014-03-16 ميوثينات إنترلوكين 2 لتمدد الخلايا المنظمة t JO3796B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361784669P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
JO3796B1 true JO3796B1 (ar) 2021-01-31

Family

ID=50680166

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2014/0119A JO3796B1 (ar) 2013-03-14 2014-03-16 ميوثينات إنترلوكين 2 لتمدد الخلايا المنظمة t

Country Status (41)

Country Link
US (8) US9580486B2 (ar)
EP (2) EP2970441B1 (ar)
JP (5) JP6450365B2 (ar)
KR (5) KR20220101009A (ar)
CN (2) CN105358570B (ar)
AP (1) AP2015008737A0 (ar)
AR (1) AR095541A1 (ar)
AU (2) AU2014236316B2 (ar)
BR (1) BR112015022440B1 (ar)
CA (3) CA2905141A1 (ar)
CL (2) CL2015002686A1 (ar)
CR (2) CR20200004A (ar)
CY (2) CY1121767T1 (ar)
DK (2) DK2970423T3 (ar)
EA (2) EA032863B1 (ar)
ES (2) ES2737598T3 (ar)
HK (1) HK1220695A1 (ar)
HR (2) HRP20190970T1 (ar)
HU (2) HUE044321T2 (ar)
IL (2) IL241349B (ar)
JO (1) JO3796B1 (ar)
LT (2) LT2970441T (ar)
MA (2) MA38477B1 (ar)
ME (2) ME03437B (ar)
MX (2) MX366854B (ar)
MY (2) MY172991A (ar)
NZ (1) NZ751148A (ar)
PE (1) PE20151763A1 (ar)
PH (1) PH12015502051A1 (ar)
PL (2) PL2970441T3 (ar)
PT (2) PT2970441T (ar)
RS (2) RS58791B1 (ar)
SG (2) SG11201507420UA (ar)
SI (2) SI2970423T1 (ar)
SM (2) SMT201900301T1 (ar)
TN (1) TN2015000416A1 (ar)
TR (2) TR201910802T4 (ar)
TW (3) TWI709572B (ar)
UA (1) UA119140C2 (ar)
UY (1) UY35454A (ar)
WO (2) WO2014153063A1 (ar)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US20190202898A9 (en) * 2012-04-03 2019-07-04 Novelmed Therapeutics, Inc. AGLYCOSYLATED ANTI-C3b ANTIBODIES AND USES THEREOF
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
CA2887050A1 (en) * 2012-10-04 2014-04-10 Novelmed Therapeutics, Inc. Alternative pathway specific antibodies for treating hemolytic diseases
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
RS57393B1 (sr) 2013-03-15 2018-09-28 Hoffmann La Roche Il-22 polipeptiidi i il-22 fuzioni proteini i metode za njihovu upotrebu
AP2015008732A0 (en) 2013-03-15 2015-09-30 Amgen Inc Human pac1 antibodies
US11098099B2 (en) 2014-02-06 2021-08-24 Hoffmann-La Roche Inc. Interleukin-2 fusion proteins and uses thereof
AU2015292889C1 (en) 2014-07-21 2023-01-19 Delinia, Inc. Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases
EP3482766B1 (en) 2014-08-11 2020-05-20 Delinia, Inc. Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
EP3194435A1 (en) 2014-09-15 2017-07-26 Amgen Inc. Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
DK3233192T3 (da) * 2014-12-15 2021-07-19 Univ Washington Sammensætninger og fremgangsmåder til målrettet cytokinindgivelse
IL283764B2 (en) 2015-04-10 2024-01-01 Amgen Inc Interleukin-2 muteins for the expansion of t-regulatory cells
PE20180132A1 (es) * 2015-04-10 2018-01-18 Amgen Inc Muteinas de interleuquina 2 para la expansion de celulas t regulatorias
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
US10822408B2 (en) 2015-12-15 2020-11-03 Amgen Inc. PACAP antibodies and uses thereof
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
PT3411402T (pt) * 2016-02-03 2022-02-01 Amgen Inc Construtos de anticorpos biespecíficos engajadores de células t contra bcma e cd3
EA039859B1 (ru) * 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
CN109311979A (zh) * 2016-02-03 2019-02-05 安进研发（慕尼黑）股份有限公司 Psma和cd3双特异性t细胞接合抗体构建体
WO2017136818A2 (en) 2016-02-05 2017-08-10 Washington University Compositions and methods for targeted cytokine delivery
CN107287273B (zh) * 2016-03-31 2021-03-09 复旦大学附属妇产科医院 表达Tim-3的外周血NK细胞在制备自然流产生物标记物中的用途
EP3443001A4 (en) 2016-04-11 2020-04-29 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
CN109071623B (zh) * 2016-05-04 2022-05-27 美国安进公司 用于扩增t调节性细胞的白细胞介素-2突变蛋白
WO2017220704A1 (en) 2016-06-22 2017-12-28 David Klatzmann Genetically modified t lymphocytes
WO2018027025A1 (en) * 2016-08-03 2018-02-08 Oncomed Pharmaceuticals, Inc. Cd40-binding agents and uses thereof
KR101928981B1 (ko) * 2016-09-02 2018-12-13 고려대학교 산학협력단 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 IL-21 (heterodimeric Fc-fused IL-21) 및 이를 포함하는 약제학적 조성물
CN110167957A (zh) 2016-11-08 2019-08-23 德里尼亚公司 用于治疗自身免疫疾病的il-2变体
EP3551749B1 (en) 2016-12-07 2023-09-27 East Carolina University Compositions and methods for in vitro cultivation and/or expansion of regulatory t cells
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
CA3064435A1 (en) 2017-05-24 2018-11-29 Pandion Therapeutics, Inc. Targeted immunotolerance
CA3076630A1 (en) 2017-10-04 2019-04-11 Amgen Inc. Transthyretin immunoglobulin fusions
EP3713592A4 (en) 2017-11-21 2022-01-12 The Board of Trustees of the Leland Stanford Junior University INTERLEUKIN-2 PARTIAL AGONISTS
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
JP2021505156A (ja) * 2017-12-06 2021-02-18 パンディオン・オペレーションズ・インコーポレイテッド 標的化免疫寛容
CN111432831B (zh) * 2017-12-06 2024-08-16 潘迪恩运营公司 Il-2突变蛋白及其用途
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
MX2020006322A (es) 2017-12-19 2020-09-18 Xencor Inc Proteinas de fusion il-2 fc modificadas.
KR102740971B1 (ko) 2017-12-27 2024-12-11 쿄와 기린 가부시키가이샤 Il-2 개변체
SG11202006610YA (en) 2018-01-12 2020-08-28 Amgen Inc Pac1 antibodies and uses thereof
BR112020015512A2 (pt) 2018-02-01 2021-01-26 Nkmax Co., Ltd. método de produção de células exterminadoras naturais e composição para tratamento de câncer
US11534479B2 (en) 2018-02-16 2022-12-27 Iltoo Pharma Use of interleukin 2 for treating Sjögren's syndrome
SG11202009017WA (en) * 2018-03-28 2020-10-29 Bristol Myers Squibb Co Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
JP7268059B2 (ja) 2018-06-07 2023-05-02 コリア リサーチ インスティチュート オブ バイオサイエンス アンド バイオテクノロジー アグリコシル化抗体生産用形質転換マウスおよびこれから生産されたアグリコシル化抗体の用途
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
JP7477885B2 (ja) 2018-06-22 2024-05-02 キュージーン インコーポレイテッド サイトカインをベースとした生理活性化薬剤およびその使用方法
AU2019288496B2 (en) 2018-06-22 2024-11-21 Cugene Inc. Interleukin-2 variants and methods of uses thereof
CA3104386A1 (en) 2018-07-02 2020-01-09 Amgen Inc. Anti-steap1 antigen-binding protein
WO2020007937A1 (en) 2018-07-03 2020-01-09 Iltoo Pharma Use of interleukin-2 for treating systemic sclerosis
EP3836954A1 (en) 2018-08-13 2021-06-23 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
CA3118397A1 (en) * 2018-11-01 2020-05-07 Shandong Newtime Pharmaceutical Co., Ltd. Bispecific antibody targeting cd3 and bcma, and uses thereof
US20220088145A1 (en) 2019-02-08 2022-03-24 The Uab Research Foundation Immunotherapy for the treatment and prevention of inflammatory bowel disease
JP7570338B2 (ja) 2019-02-15 2024-10-21 インテグラル・モレキュラー・インコーポレイテッド クローディン６抗体及びその使用
JP2022520632A (ja) 2019-02-15 2022-03-31 インテグラル・モレキュラー・インコーポレイテッド 共通軽鎖を含む抗体及びその使用
KR20220008811A (ko) 2019-03-29 2022-01-21 엥스띠뛰 퀴리 변형된 생물학적 활성을 갖는 인터류킨-2 변이체.
CN111944036B (zh) * 2019-05-14 2024-09-06 上海盖浦生物科技有限公司 一种增殖免疫细胞的突变体蛋白
CN114679909A (zh) 2019-05-20 2022-06-28 潘迪恩运营公司 MAdCAM靶向的免疫耐受
AU2020289587A1 (en) 2019-06-07 2021-12-23 Amgen Inc. Bispecific binding constructs with selectively cleavable linkers
MX2021015976A (es) 2019-07-08 2022-02-10 Amgen Inc Fusiones de inmunoglobulina y transtiretina multiespecificas.
BR112022001415A2 (pt) 2019-07-26 2022-06-07 Visterra Inc Agentes interleucina-2 e os usos dos mesmos
PH12022550326A1 (en) * 2019-08-13 2023-03-13 Amgen Inc Interleukin-2 muteins for the expansion of t-regulatory cells
US20220340642A1 (en) 2019-09-13 2022-10-27 Kyowa Kirin Co., Ltd. Dcr3 variant
CA3154710A1 (en) 2019-10-04 2021-04-08 TAE Life Sciences Antibody compositions comprising fc mutations and site-specific conjugation properties
BR112022009521A2 (pt) * 2019-11-20 2022-08-16 Gi Cell Inc Composição de meio para cultura de células t e método para cultura de células t usando a mesma
JP2023505102A (ja) * 2019-11-29 2023-02-08 エヌケーマックス カンパニー リミテッド ナチュラルキラー細胞を製造する方法およびその組成物
AU2020401357A1 (en) 2019-12-12 2022-07-21 Assistance Publique - Hôpitaux De Paris Interleukin 2 chimeric constructs
US20230040604A1 (en) 2019-12-17 2023-02-09 Amgen Inc. Interleukin-2 in combination with tnf receptor family members for the expansion of t-regulatory cells
WO2021127487A2 (en) 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
IL294659A (en) 2020-01-14 2022-09-01 Synthekine Inc Biased il2 muteins methods and compositions
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
KR20220164569A (ko) * 2020-04-06 2022-12-13 렁 바이오테크놀로지 피비씨 모듈식 합성 수용체 및 사용 방법
JP2023526282A (ja) 2020-05-13 2023-06-21 ボナム セラピューティクス，インク． タンパク質複合体の組成物及びその使用方法
WO2021247812A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Bispecific binding constructs
US20230226203A1 (en) * 2020-06-18 2023-07-20 Proviva Therapeutics (Hong Kong) Limited Activatable procytokines
CN112048018B (zh) * 2020-08-31 2021-10-08 南方医科大学 一种嵌合t细胞生长因子及其应用
KR20230061490A (ko) * 2020-09-04 2023-05-08 산둥심시어 바이오파마슈티칼 씨오., 엘티디. Il-2 돌연변이체 및 그 응용
AU2021369823A1 (en) 2020-10-29 2023-06-01 Bristol-Myers Squibb Company Fusion proteins for the treatment of disease
IL303205A (en) 2020-12-03 2023-07-01 Amgen Inc Immunoglobuline constructs with multiple binding domains
MX2023006599A (es) 2020-12-04 2023-06-19 Visterra Inc Metodos de uso de agentes de interleucina-2.
TW202304994A (zh) 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗ｉｌ－２ｒ抗體及使用方法
TW202306584A (zh) 2021-05-27 2023-02-16 法商賽諾菲公司 具有對Fc受體之增強親和力及改良熱穩定性的Fc變體
EP4370139A2 (en) 2021-07-14 2024-05-22 Synthekine, Inc. Methods and compositions for use in cell therapy of neoplastic disease
EP4380970A1 (en) * 2021-08-06 2024-06-12 Amgen Inc. Isolation of therapeutic protein
MX2024004291A (es) 2021-10-06 2024-06-28 Iltoo Pharma Construcciones quiméricas de interleucina 2 con especificidad de direccionamiento a tejidos inflamados.
EP4417626A1 (en) * 2021-10-14 2024-08-21 Latticon (Suzhou) Biopharmaceuticals Co., Ltd. Novel antibody-cytokine fusion protein, preparation method therefor and use thereof
CA3234966A1 (en) 2021-10-14 2023-04-20 Teneobio, Inc. Mesothelin binding proteins and uses thereof
MX2024006746A (es) * 2021-12-01 2024-08-09 Visterra Inc Métodos de uso de agentes de interleucina-2.
EP4476250A1 (en) 2022-02-07 2024-12-18 Vib Vzw Engineered stabilizing aglycosylated fc-regions
AU2023225012A1 (en) * 2022-02-22 2024-09-12 The Regents Of The University Of Michigan Compositions and methods for treating autoimmune disorders
WO2023180527A1 (en) 2022-03-25 2023-09-28 Universität Zürich Adenoviral mediated targeting of activated immune cells
IL317227A (en) 2022-05-27 2025-01-01 Sanofi Sa Combined natural killer (NK) cells bind to NKP46 and BCMA variants with FC engineering
AU2023312905A1 (en) 2022-07-27 2025-01-16 Teneobio, Inc. Mesothelin binding proteins and uses thereof
WO2024056154A1 (en) 2022-09-12 2024-03-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Interleukin-2 for use in treating autism spectrum disorder
WO2024077044A1 (en) 2022-10-05 2024-04-11 Amgen Inc. Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
TW202432574A (zh) 2022-10-25 2024-08-16 比利時商艾伯霖克斯公司 具有增強的效應子功能之糖基工程化Ｆｃ變體多肽
TW202430574A (zh) 2022-11-30 2024-08-01 美商積分分子股份有限公司 針對密連蛋白６之抗體，包括其雙特異性格式
WO2024151515A2 (en) 2023-01-09 2024-07-18 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
WO2024178056A1 (en) 2023-02-21 2024-08-29 Teneobio, Inc. C-kit binding proteins, chimeric antigen receptors, and uses thereof

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US233A (en) 1837-06-14 Improvement in plows
US4447A (en) 1846-04-04 Car- wheel
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
EP0351410A1 (en) 1987-03-18 1990-01-24 3i RESEARCH EXPLOITATION LIMITED Complement-binding peptide
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
CA2062582C (en) 1991-03-27 1996-03-26 Tse-Wen Chang Methods and substances for recruiting therapeutic agents to solid tissues
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6239328B1 (en) 1992-10-05 2001-05-29 North Carolina State University Method for reducing expression variability of transgenes in plant cells
US6037525A (en) 1996-08-01 2000-03-14 North Carolina State University Method for reducing expression variability of transgenes in plant cells
FR2752462B1 (fr) 1996-08-14 1998-10-23 Essilor Int Procede d'incorporation d'additifs dans un article ophtalmique au moyen d'un fluide a l'etat supercritique
US6245974B1 (en) 1997-08-06 2001-06-12 North Carolina State University Matrix attachment regions
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US6177612B1 (en) 1998-07-31 2001-01-23 Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture And Agri-Food Canada Matrix attachment regions
US6388066B1 (en) 1998-09-29 2002-05-14 Pioneer Hi-Bred International, Inc. MAR/SAR elements flanking RSYN7-driven construct
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR100408844B1 (ko) 2000-07-29 2003-12-06 한국산업기술평가원 동물세포 발현벡터
JP2004528014A (ja) * 2000-12-07 2004-09-16 イーライ・リリー・アンド・カンパニー Ｇｌｐ−１融合タンパク質
WO2002048379A1 (en) 2000-12-15 2002-06-20 Pangen Biotech Inc. Expression vector for animal cell containing nuclear matrix attachment region fo interferon beta
SG141239A1 (en) 2001-01-26 2008-04-28 Selexis Sa Matrix attachment regions and methods for use thereof
AU2002357784B2 (en) 2001-12-04 2008-07-31 Merck Patent Gmbh Immunocytokines with modulated selectivity
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
JP4629047B2 (ja) * 2003-06-12 2011-02-09 イーライ リリー アンド カンパニー Ｇｌｐ−１アナログ複合タンパク質
US7569215B2 (en) 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
WO2005047512A2 (en) 2003-11-12 2005-05-26 Shering Corporation Plasmid system for multigene expression
CN1930300A (zh) * 2004-03-05 2007-03-14 希龙公司 预测患者治疗药物耐受性的体外试验系统
BRPI0508470A (pt) 2004-03-05 2007-07-31 Chiron Corp sistema de teste in vitro para prever toleráncia do paciente aos agentes terapêuticos
CN101065151B (zh) * 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
US20060280728A1 (en) * 2005-05-06 2006-12-14 Providence Health System Trimeric OX40-immunoglobulin fusion protein and methods of use
KR20080031684A (ko) 2005-06-14 2008-04-10 암젠 인코포레이티드 자가 - 완충성 단백질 제형
US20070036786A1 (en) * 2005-07-11 2007-02-15 Nadine Tuaillon Method of treating autoimmune disease using humanized anti-CD16A antibodies
WO2008112325A2 (en) 2007-03-15 2008-09-18 Biogen Idec Ma Inc. Treatment of autoimmune disorders
GB0623539D0 (en) 2006-11-24 2007-01-03 Avidex Ltd Polypeptides
US20090016935A1 (en) 2007-07-09 2009-01-15 Andrianov Alexander K Coating formulations including polyphosphazene polyelectrolytes and biologically active agents and asperities coated with such formulations
US7695963B2 (en) 2007-09-24 2010-04-13 Cythera, Inc. Methods for increasing definitive endoderm production
US8906356B2 (en) * 2007-11-05 2014-12-09 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
WO2010085495A1 (en) 2009-01-21 2010-07-29 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
BRPI1006998A2 (pt) * 2009-01-23 2015-08-25 Biogen Idec Inc Polipeptídeos fc estabilizados com função efetora reduzida e métodos de uso
EP2504360B1 (en) 2009-11-23 2018-08-15 Amgen Inc. Monomeric antibody fc
KR20120107122A (ko) * 2009-12-22 2012-09-28 노파르티스 아게 치료법에서 사용하기 위한 ４가 ｃｄ４７―항체 불변 영역 융합 단백질
PL2646470T3 (pl) 2010-11-30 2017-07-31 F.Hoffmann-La Roche Ag Przeciwciała przeciw receptorowi transferyny o niskim powinowactwie oraz ich zastosowanie do przenoszenia terapeutycznego scfv przez barierę krew-mózg
EP3489255B1 (en) * 2011-02-10 2021-06-16 Roche Glycart AG Mutant interleukin-2 polypeptides
US20140112926A1 (en) 2011-03-16 2014-04-24 Amgen Inc. Fc VARIANTS
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
CA2859755C (en) 2011-12-23 2021-04-20 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
RU2014136332A (ru) 2012-02-06 2016-03-27 Дженентек, Инк. Композиции и способы применения ингибиторов csf1r
WO2013177062A2 (en) 2012-05-21 2013-11-28 Genentech, Inc. Methods for improving safety of blood-brain barrier transport
US9580486B2 (en) * 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
RS57393B1 (sr) * 2013-03-15 2018-09-28 Hoffmann La Roche Il-22 polipeptiidi i il-22 fuzioni proteini i metode za njihovu upotrebu
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
EP2970423A2 (en) 2016-01-20
CL2015002669A1 (es) 2016-09-09
IL241349B (en) 2018-08-30
AP2015008737A0 (en) 2015-09-30
MA38477B1 (fr) 2019-05-31
US20140286898A1 (en) 2014-09-25
TW202115106A (zh) 2021-04-16
KR20220101009A (ko) 2022-07-18
CA3149348A1 (en) 2014-09-25
EA032863B1 (ru) 2019-07-31
EP2970441A4 (en) 2016-11-23
TR201910802T4 (tr) 2019-08-21
EP2970423B1 (en) 2019-04-24
PT2970423T (pt) 2019-07-23
US10093711B2 (en) 2018-10-09
TW202005979A (zh) 2020-02-01
JP7227951B2 (ja) 2023-02-22
CA2906708C (en) 2022-05-03
BR112015022440B1 (pt) 2022-08-16
CA2906708A1 (en) 2014-09-25
JP2021040630A (ja) 2021-03-18
JP2023053148A (ja) 2023-04-12
TR201908362T4 (tr) 2019-06-21
LT2970423T (lt) 2019-05-27
PL2970441T3 (pl) 2019-09-30
EA201591766A1 (ru) 2016-02-29
PL2970423T3 (pl) 2019-10-31
HUE043488T2 (hu) 2019-08-28
DK2970441T3 (da) 2019-06-03
PH12015502051B1 (en) 2016-01-18
TWI709572B (zh) 2020-11-11
EP2970441B1 (en) 2019-03-06
RS58854B1 (sr) 2019-07-31
ES2720225T3 (es) 2019-07-18
UA119140C2 (uk) 2019-05-10
HK1220695A1 (zh) 2017-05-12
IL241622B (en) 2020-09-30
DK2970423T3 (da) 2019-07-08
CA2905141A1 (en) 2014-09-25
CY1121767T1 (el) 2020-07-31
CR20150557A (es) 2015-11-10
CN105143253A (zh) 2015-12-09
RS58791B1 (sr) 2019-07-31
AR095541A1 (es) 2015-10-21
US20140343252A1 (en) 2014-11-20
MY172991A (en) 2019-12-17
MA49207B1 (fr) 2022-08-31
WO2014153111A2 (en) 2014-09-25
LT2970441T (lt) 2019-06-10
US20180319859A1 (en) 2018-11-08
AU2014236316A1 (en) 2015-10-08
TW201522366A (zh) 2015-06-16
MX366854B (es) 2019-07-26
AU2014236281A1 (en) 2015-09-24
US20240327485A1 (en) 2024-10-03
TN2015000416A1 (en) 2017-01-03
CN105358570A (zh) 2016-02-24
JP2016518823A (ja) 2016-06-30
HRP20191075T1 (hr) 2019-09-20
TWI784288B (zh) 2022-11-21
US10562950B2 (en) 2020-02-18
JP2016514161A (ja) 2016-05-19
PE20151763A1 (es) 2015-12-10
US9546203B2 (en) 2017-01-17
MX2015012912A (es) 2015-12-03
JP2019058182A (ja) 2019-04-18
CY1121823T1 (el) 2020-07-31
SMT201900415T1 (it) 2019-09-09
US10829535B2 (en) 2020-11-10
US11976102B2 (en) 2024-05-07
KR20150130342A (ko) 2015-11-23
CN105143253B (zh) 2021-02-19
US20170081382A1 (en) 2017-03-23
CN105358570B (zh) 2019-11-12
SI2970441T1 (sl) 2019-07-31
CL2015002686A1 (es) 2016-04-15
ME03437B (me) 2020-01-20
US9580486B2 (en) 2017-02-28
AU2014236281B2 (en) 2018-03-08
US20210094997A1 (en) 2021-04-01
BR112015022440A2 (pt) 2017-10-24
PT2970441T (pt) 2019-06-11
EA034326B1 (ru) 2020-01-28
CA3149348C (en) 2023-09-12
KR102418771B1 (ko) 2022-07-08
US9932380B2 (en) 2018-04-03
MX2015012890A (es) 2015-12-03
TWI687435B (zh) 2020-03-11
SMT201900301T1 (it) 2019-07-11
BR112015023145A2 (pt) 2017-11-21
HRP20190970T1 (hr) 2019-07-26
NZ712066A (en) 2021-05-28
US20180237489A1 (en) 2018-08-23
HUE044321T2 (hu) 2019-10-28
JP6450365B2 (ja) 2019-01-09
EA201591731A1 (ru) 2016-04-29
NZ751148A (en) 2021-05-28
SG11201507574VA (en) 2015-10-29
ME03482B (me) 2020-01-20
ES2737598T3 (es) 2020-01-15
US20170137485A1 (en) 2017-05-18
MY202248A (en) 2024-04-19
MA38477A1 (fr) 2017-09-29
KR20250002742A (ko) 2025-01-07
UY35454A (es) 2014-09-30
IL241349A0 (en) 2015-11-30
WO2014153111A3 (en) 2014-11-13
KR20150127185A (ko) 2015-11-16
SI2970423T1 (sl) 2019-08-30
AU2014236316B2 (en) 2018-11-01
SG11201507420UA (en) 2015-10-29
KR102219124B1 (ko) 2021-02-22
JP6480409B2 (ja) 2019-03-13
MA49207A1 (fr) 2021-09-30
PH12015502051A1 (en) 2016-01-18
CR20200004A (es) 2020-03-11
KR20230157526A (ko) 2023-11-16
WO2014153063A1 (en) 2014-09-25
AU2014236316A9 (en) 2018-11-08
EP2970441A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
TN2015000416A1 (en) Interleukin-2 muteins for the expansion of t-regulatory cells
SA517390134B1 (ar) مركبات ميوتين إنترلوكين-2 لتمديد خلايا تائية منظمة
WO2016164937A3 (en) Interleukin-2 muteins for the expansion of t-regulatory cells
MX2023008559A (es) Proteínas de fusión fc heterodiméricas il15/il15ra.
PH12014502767A1 (en) Interleukin-2 fusion proteins and uses thereof
BR112015013525A2 (pt) método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
NZ630848A (en) Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
SG195306A1 (en) Purification of biological products by constrained cohydration chromatography
GB2513768A (en) Complexes of cytomegalovirus proteins
PH12019501588A1 (en) Pillow
MX2023009405A (es) Muteinas de interleuquina 2 para la expansion de celulas t regulatorias.
EP4385573A3 (en) Interleukin-2 muteins for the expansion of t-regulatory cells
WO2012115903A3 (en) Yeast strain for the production of proteins with modified o-glycosylation
WO2015061464A3 (en) Recombinant glycoproteins and uses thereof
WO2015003811A8 (en) Methods for producing sialylated therapeutic proteins
WO2007146163A3 (en) Fc-fusion proteins with reduced fc-mediated effector activities
BR112017003074A2 (pt) Célula isolada, e, métodos de produção de uma proteína recombinante de interesse e de glicosilação de um substrato de proteína de n- glicano.